Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2020 Net Income-$88.77M-$88.77MN/M vs Q3 2020 EPS Diluted-$1.56-$1.56N/M vs Q3 2020 Operating Income-$91,152,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$85,162,000N/M ended Sep 30, 2021 · filed Nov 3, 2021 · 34 d after period end